Ludwig-Maximilians-Universität, Chair of Metabolic Biochemistry
print


Breadcrumb Navigation


Content

Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) increase the risk for several neurodegenerative diseases including Alzheimer's disease and frontotemporal dementia (FTD). Homozygous endogenous expression of the TREM2 p.T66M mutation impairs microglia function, brain perfusion and glucose metabolism, suggesting that microglial TREM2 acts as a signaling hub. more

Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) are linked to an increased risk for several neurodegenerative disorders. Trans-criptomic and functional studies reveal that TREM2 deficient microglia display a homeostatic mRNA signature and are impaired in chemotaxis and their response to neuronal injury. more